10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Crude Oil Surges Over 2%; US Leading Economic Index Falls In December
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Monday.
The Dow traded up 0.41% to 38,018.23 while the NASDAQ rose 0.30% to 15,356.67. The S&P 500 also rose, gaining, 0.25% to 4,851.78.
Why Is HIV Drug Giant Gilead Stock Falling Monday?
Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Despite numerical OS improvement, further exploration is planned.
EXCLUSIVE: The ‘Buy Everything’ Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc.
AbbVie’s Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Nasdaq 100 Snaps Longest Negative Streak In 14 Months As Tech Stocks Find Relief On Mixed Data
The Nasdaq 100 ended the first week of 2024 on a positive note, ending a five-session losing streak, despite volatile trading and conflicting economic data.
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate